WO2012111961A3 - 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제 - Google Patents

티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제 Download PDF

Info

Publication number
WO2012111961A3
WO2012111961A3 PCT/KR2012/001108 KR2012001108W WO2012111961A3 WO 2012111961 A3 WO2012111961 A3 WO 2012111961A3 KR 2012001108 W KR2012001108 W KR 2012001108W WO 2012111961 A3 WO2012111961 A3 WO 2012111961A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained
tianeptine
pharmaceutically acceptable
acceptable salt
tablet containing
Prior art date
Application number
PCT/KR2012/001108
Other languages
English (en)
French (fr)
Other versions
WO2012111961A2 (ko
Inventor
박정수
심지연
박준상
Original Assignee
지엘팜텍주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지엘팜텍주식회사 filed Critical 지엘팜텍주식회사
Publication of WO2012111961A2 publication Critical patent/WO2012111961A2/ko
Publication of WO2012111961A3 publication Critical patent/WO2012111961A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 티아넵틴 및 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제에 관한 것으로, 보다 상세하게는 티아넵틴 나트륨을 1일 1회 복용하도록 하기 위한 서방성 정제에 관한 것이다.
PCT/KR2012/001108 2011-02-14 2012-02-14 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제 WO2012111961A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0012969 2011-02-14
KR1020110012969A KR20120092993A (ko) 2011-02-14 2011-02-14 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제

Publications (2)

Publication Number Publication Date
WO2012111961A2 WO2012111961A2 (ko) 2012-08-23
WO2012111961A3 true WO2012111961A3 (ko) 2012-10-26

Family

ID=46673036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001108 WO2012111961A2 (ko) 2011-02-14 2012-02-14 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제

Country Status (2)

Country Link
KR (1) KR20120092993A (ko)
WO (1) WO2012111961A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6285865B2 (ja) 2011-11-14 2018-02-28 アルファシグマ ソシエタ ペル アチオニ うつ病を有する対象のための処置レジメンを選択するためのアッセイ及び方法
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US5888542A (en) * 1996-04-24 1999-03-30 Adir Et Compagnie Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route
US6599896B1 (en) * 1999-04-07 2003-07-29 Les Laboratoires Servier Use of tianeptine in the production of medicaments to treat neurodegenerative pathologies
US20060018933A1 (en) * 2002-08-05 2006-01-26 Navin Vaya Novel drug delivery system
KR100552420B1 (ko) * 2003-06-05 2006-02-16 조영관 난용성 약물의 서방형 정제
KR20070094110A (ko) * 2006-03-16 2007-09-20 (주) 벡스코아 제어 방출 제형
KR100798730B1 (ko) * 2006-06-12 2008-01-29 신풍제약주식회사 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
KR20080073989A (ko) * 2007-02-07 2008-08-12 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
KR20100089532A (ko) * 2009-02-04 2010-08-12 한국유나이티드제약 주식회사 제어 방출성 아세클로페낙을 함유하는 경구 제제의 조성물 및 그의 제조방법

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US5888542A (en) * 1996-04-24 1999-03-30 Adir Et Compagnie Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route
US6599896B1 (en) * 1999-04-07 2003-07-29 Les Laboratoires Servier Use of tianeptine in the production of medicaments to treat neurodegenerative pathologies
US20060018933A1 (en) * 2002-08-05 2006-01-26 Navin Vaya Novel drug delivery system
KR100552420B1 (ko) * 2003-06-05 2006-02-16 조영관 난용성 약물의 서방형 정제
KR20070094110A (ko) * 2006-03-16 2007-09-20 (주) 벡스코아 제어 방출 제형
KR100798730B1 (ko) * 2006-06-12 2008-01-29 신풍제약주식회사 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
KR20080073989A (ko) * 2007-02-07 2008-08-12 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
KR20100089532A (ko) * 2009-02-04 2010-08-12 한국유나이티드제약 주식회사 제어 방출성 아세클로페낙을 함유하는 경구 제제의 조성물 및 그의 제조방법

Also Published As

Publication number Publication date
WO2012111961A2 (ko) 2012-08-23
KR20120092993A (ko) 2012-08-22

Similar Documents

Publication Publication Date Title
HK1198132A1 (en) Tamper-resistant tablet providing immediate drug release
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
ZA201309299B (en) Tamper-resistant tablet providing immediate drug release
IL216522A (en) Durable dosage form, packing containing it and method of preparation
PL2257305T3 (pl) Nowy farmaceutyczny preparat do leczenia stanu przedrzucawkowego
IL222919A (en) Alcohol-resistant oral form
DK2442790T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyolkomplekser
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2010092090A3 (en) Novel salts of sitagliptin
IL232966B (en) Pharmaceutical tablet for controlled release and method for its production
EP2647381A4 (en) MELTING TABLET
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
EP2804596B8 (en) Transmucosal administration system for a pharmaceutical drug
HK1181318A1 (en) Ivabradine or its pharmaceutically acceptable salts sustained-release preparation
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
IL218643A0 (en) Orally disintegrating pharmaceutical dosage form containing aripiprazole
GB2455875B (en) A process for the preparation of an orally administered unit dose tablet
EP2612657A4 (en) TABLET WITH ORAL DISINTEGRATION
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2012111961A3 (ko) 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
GB2475701B (en) A process for the preparation of an orally administered anthelmintic unit dose tablet
WO2012016646A9 (de) Quetiapin-tabletten
WO2011107921A3 (en) Modified release composition of milnacipran
HU1000444D0 (en) Process for the preparation of a pharmaceutical active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12746901

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12746901

Country of ref document: EP

Kind code of ref document: A2